OBJECTIVES: To evaluate the differences in statin usage among patients with confirmed CAD or related risk factors between Europe & US to derive insights into practice behavior that may impact disease burden. METHODS: Data from a large multi-country cardiovascular research initiative involving primary-care physicians (PCPs) and specialists to collect outpatient chart data (for cardiovascular patients) was analyzed to evaluate the use of statins (including high-doses: 80 mg atorvastatin/simvastatin, =20 mg rosuvastatin) among patients with CAD or CAD-equivalent (myocardial Infarction, PCI/CABG/diabetes), peripheral vascular disease (PVD), cerebral ischemia (CI), Diabetes (any-type) and other risk factors (CAD-RF: hypertension/low-HDL/age/sex/smoking/family-history of CVD). Patient conditions/risk-factors were not mutually exclusive. Analysis included 2006 data from US and 5 major countries in Europe (EU5, reported in aggregate). RESULTS: In total, 23,321 & 5,008 patient charts were abstracted by 2299 & 587 PCPs/specialists in EU5 & U.S respectively. Distribution of patients was (condition:EU5, US) – CAD: 28.5%, 23.0%, CAD-equivalent: 66.1%, 65.1%, diabetes: 46.5%, 52.8%, PVD: 6.6%, 7.4%, cerebral ischemia: 4.4%, 2.8%, CAD-RF